Business UpdateAug 13, 2026, 04:47 PM
Adagio Medical Updates on vCLAS Ultra, Targets Q4 2026 FDA Approval
AI Summary
Adagio Medical Holdings, Inc. released an updated corporate presentation for investors and analysts, detailing the progress and potential of its vCLAS Ultra low-temperature cryoablation technology. The presentation highlights the significant market opportunity in VT ablation, positive clinical trial results, and a clear regulatory pathway. The company anticipates FDA approval for its first-generation vCLAS system by Q4 2026 or Q1 2027, with the next-gen vCLAS Ultra expected by Q1 2028.
Key Highlights
- Updated corporate presentation made available to investors and analysts.
- vCLAS Ultra targets a $5.8B global VT ablation market, currently 6% penetrated.
- FULCRUM-VT pivotal study showed 84% freedom from ICD shock at 6 months.
- FULCRUM-VT study reported a 2.4% major adverse event rate.
- FDA approval for vCLAS (first generation) expected Q4 2026 / Q1 2027.
- FDA approval for next-gen vCLAS Ultra system expected Q1 2028.
- Cash and cash equivalents stood at $7.7M as of June 30, 2026.
- Secured an October 2025 PIPE of up to $50M to advance vCLAS technologies.
Price Impact
More from ADGM